arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

ELI LILLY & Co

LLY
$1362.32 ▼ -55.75 (-3.93%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
76 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
70
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

ELI LILLY & Co demonstrates solid fundamentals with strength in Return on Common Equity (%). However, watch Debt to Equity which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $1.2T
Dividend Yield —
Revenue Growth 38.6% ↘
Op. Margin —
ROIC —
FCF / Share $12.78 ↗
Trailing P/E 188.4x
Price / Book 30.2x
FCF Yield 0.9%
Debt / Equity 1.17
info Valuation on last close. End-of-day price, Nov 5, 2026.

76-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$24.40B
↑ +38.6% —
Net Income Profit after all expenses
$6.45B
↑ +15.6% —
FCF / Share Free cash flow per share
$12.78
↑ +6.7% —
Long-Term Debt Long-term obligations
$46.99B
↓ -1.8% —
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability ↑
91
Returns ↑
99
Financial Health ↓
17
Cash Quality ↓
55

Dividend History

Dividend / share · sourced from SEC filings
$6.23 Latest / share
+15.4% YoY
+14.4% 9-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 20 years · 76 quarters